Reducing breast cancer recurrences with CDK4/6 inhibitor treatment of HR-positive, HER2-negative early stage breast cancer from a societal perspective
{{output}}
Background: Hormone receptor (HR)-positive and HER2 receptor-negative breast cancer accounts for two thirds of all breast cancers. In case of distant recurrences, a non-curative strategy is usually implied. Hence, treatment optio... ...
